Philochem Ag

Philochem Ag company information, Employees & Contact Information

Explore related pages

Related company profiles:

Philochem is a fully owned daughter company of Philogen and represents the Discovery Unit of the Philogen group. Philochem is based in Otelfingen (Zurich, Switzerland) and was founded in 2006, with the mission to innovate ligand discovery and medicinal target identification. Philochem has discovered innovative methodologies for biotechnology product development: - isolation of human monoclonal antibodies from large combinatorial libraries; - development of armed antibodies (immunocytokines and antibody-drug conjugates); - discovery and validation of vascular markers of pathology using a perfusion-based chemical proteomics approach; - design, construction and screening of DNA-encoded chemical libraries of unprecedented quality and size. These technologies are integrated into drug discovery programs. The most promising candidate products are further developed in the Siena-based Philogen facilities. Here production according to GMP standards and clinical trials are conducted with the aim of developing superior products for the imaging and treatment of serious angiogenesis-related diseases. Philochem has a proven track record in partnering activities, and is currently involved in several projects with leading pharmaceutical companies interested in Philochem’s innovative technology platforms.

Company Details

Employees
48
Founded
-
Address
Libernstrasse 3, Otelfingen,8112,switzerland
Phone
(+41) 43 544 88 00
Email
in****@****chem.ch
Industry
Research Services
NAICS
Scientific Research and Development Services
Research and Development in the Physical, Engineering, and Life Sciences
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Keywords
Follow.
HQ
Otelfingen
Looking for a particular Philochem Ag employee's phone or email?

Philochem Ag Questions

News

Bristol Myers bolsters radiopharma portfolio with PhiloChem deal - BioPharma Dive

Bristol Myers bolsters radiopharma portfolio with PhiloChem deal BioPharma Dive

Phenylalanine-Based DNA-Encoded Chemical Libraries for the Discovery of Potent and Selective Small Organic Ligands Against Markers of Cancer and Immune Cells - Wiley

Phenylalanine-Based DNA-Encoded Chemical Libraries for the Discovery of Potent and Selective Small Organic Ligands Against Markers of Cancer and Immune Cells Wiley

Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus r - GlobeNewswire

Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus r GlobeNewswire

BMS-owned RayzeBio licenses Philochem asset for $350 million up front - Chemical & Engineering News

BMS-owned RayzeBio licenses Philochem asset for $350 million up front Chemical & Engineering News

Philochem Licenses OncoACP3 Worldwide Rights to RayzeBio - Contract Pharma

Philochem Licenses OncoACP3 Worldwide Rights to RayzeBio Contract Pharma

Philochem licenses worldwide rights for OncoACP3 to BMS unit - The Pharma Letter

Philochem licenses worldwide rights for OncoACP3 to BMS unit The Pharma Letter

BMS Expands Radiopharma Presence With $1.35B Biobucks Deal for Philochem - BioSpace

BMS Expands Radiopharma Presence With $1.35B Biobucks Deal for Philochem BioSpace

BMS bags rights to Philochem's prostate cancer radiotracer in $1.35B deal - FirstWord Pharma

BMS bags rights to Philochem's prostate cancer radiotracer in $1.35B deal FirstWord Pharma

Bristol Myers Squibb Is Paying $350M to Expand Its Reach in Radiopharmaceuticals to Prostate Cancer - MedCity News

Bristol Myers Squibb Is Paying $350M to Expand Its Reach in Radiopharmaceuticals to Prostate Cancer MedCity News

BMS expands radiopharma pipeline via RayzeBio's $1.3B prostate cancer drug deal - Fierce Biotech

BMS expands radiopharma pipeline via RayzeBio's $1.3B prostate cancer drug deal Fierce Biotech

BMS' radiopharma unit builds with $1.35bn Philochem deal - pharmaphorum

BMS' radiopharma unit builds with $1.35bn Philochem deal pharmaphorum

Philochem licenses prostate cancer radiopharmaceutical to Bristol Myers in deal worth up to $1.35 billion - DOTmed

Philochem licenses prostate cancer radiopharmaceutical to Bristol Myers in deal worth up to $1.35 billion DOTmed

Bristol-Myers' RayzeBio signs a license deal with Philochem - Seeking Alpha

Bristol-Myers' RayzeBio signs a license deal with Philochem Seeking Alpha

Philochem patents new radiolabeled FAP ligands - BioWorld MedTech

Philochem patents new radiolabeled FAP ligands BioWorld MedTech

Molecular Evolution of Multivalent OncoFAP Derivatives with Enhanced Tumor Uptake and Prolonged Tumor Retention - ACS Publications

Molecular Evolution of Multivalent OncoFAP Derivatives with Enhanced Tumor Uptake and Prolonged Tumor Retention ACS Publications

Philochem and Blue Earth Diagnostics Announce First Three - GlobeNewswire

Philochem and Blue Earth Diagnostics Announce First Three GlobeNewswire

Discovery of Glutamate Carboxypeptidase III Ligands to Compete the Uptake of [ - ACS Publications

Discovery of Glutamate Carboxypeptidase III Ligands to Compete the Uptake of [ ACS Publications

Permutational Encoding Strategy Accelerates HIT Validation from Single-Stranded DNA-Encoded Libraries - ACS Publications

Permutational Encoding Strategy Accelerates HIT Validation from Single-Stranded DNA-Encoded Libraries ACS Publications

DNA-Encoded Chemical Libraries: A Comprehensive Review with Succesful Stories and Future Challenges - ACS Publications

DNA-Encoded Chemical Libraries: A Comprehensive Review with Succesful Stories and Future Challenges ACS Publications

Mass Spectrometry-Based Method for the Determination of the Biodistribution of Tumor-Targeting Small Molecule–Metal Conjugates - ACS Publications

Mass Spectrometry-Based Method for the Determination of the Biodistribution of Tumor-Targeting Small Molecule–Metal Conjugates ACS Publications

Top Philochem Ag Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant